Evidence map›Paper›PMID 33902686›Full record

ArticleParasites & vectors2021

Synthesis of oxadiazole-2-oxide derivatives as potential drug candidates for schistosomiasis targeting SjTGR.

Gongming Li, Qingqing Guo, Chao Feng, Huan Chen, Wenjiao Zhao, Shu Li, Yang Hong, Dequn Sun

Open access · goldAbstract read
In one paragraph

Article in Parasites & vectors, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Bioinformatics and biology insights · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Gongming LiSchool of Life Science and Engineering, Southwest University of Science and Technology, Mianyang, 621010, China.
Qingqing Guo *National Reference Laboratory of Animal Schistosomiasis, Key Laboratory of Animal Parasitology of Ministry of Agriculture, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, 200241, China.
Chao FengSchool of Life Science and Engineering, Southwest University of Science and Technology, Mianyang, 621010, China.
Huan ChenSchool of Life Science and Engineering, Southwest University of Science and Technology, Mianyang, 621010, China.
Wenjiao ZhaoSchool of Life Science and Engineering, Southwest University of Science and Technology, Mianyang, 621010, China.
Shu LiMarine College, Shandong University (Weihai), Weihai, 264209, China.
Yang HongNational Reference Laboratory of Animal Schistosomiasis, Key Laboratory of Animal Parasitology of Ministry of Agriculture, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, 200241, China. hongyang@shvri.ac.cn.
Dequn SunSchool of Life Science and Engineering, Southwest University of Science and Technology, Mianyang, 621010, China. dqsun@swust.edu.cn.
Shandong University · CNSouthwest University of Science and Technology · CNChinese Academy of Agricultural Sciences · CNShanghai Veterinary Research Institute · CN

Funding

National Natural Science Foundation of China No. 31402192National Natural Science Foundation of China No. 81773560
6 · The paper itself

Abstract

backgroundSchistosomiasis is a chronic parasitic disease that affects millions of people's health worldwide. Because of the increasing drug resistance to praziquantel (PZQ), which is the primary drug for schistosomiasis, developing new drugs to treat schistosomiasis is crucial. Oxadiazole-2-oxides have been identified as potential anti-schistosomiasis reagents targeting thioredoxin glutathione reductase (TGR).

methodsIn this work, one of the oxadiazole-2-oxides derivatives furoxan was used as the lead compound to exploit a series of novel furoxan derivatives for studying inhibitory activity against both recombinant Schistosoma japonicum TGR containing selenium (rSjTGR-Sec) and soluble worm antigen protein (SWAP) containing wild-type Schistosoma japonicum TGR (wtSjTGR), in order to develop a new leading compound for schistosomiasis. Thirty-nine novel derivatives were prepared to test their activity toward both enzymes. The docking method was used to detect the binding site between the active molecule and SjTGR. The structure-activity relationship (SAR) of these novel furoxan derivatives was preliminarily analyzed.

resultsIt was found that several new derivatives, including compounds 6a-6d, 9ab, 9bd and 9be, demonstrated greater activity toward rSjTGR-Sec or SWAP containing wtSjTGR than did furoxan. Interestingly, all intermediates bearing hydroxy (6a-6d) showed excellent inhibitory activity against both enzymes. In particular, compound 6d with trifluoromethyl on a pyridine ring was found to have much higher inhibition toward both rSjTGR-Sec (half-maximal inhibitory concentration, IC

conclusionThe data obtained herein showed that 6d with trifluoromethyl on a pyridine ring could be a valuable leading compound for further study.

Indexed as

AnimalsAntigens, HelminthCrystallography, X-RayDrug Delivery SystemsEnzyme InhibitorsMolecular StructureMultienzyme ComplexesNADH, NADPH OxidoreductasesOxadiazolesSchistosoma japonicumSchistosomiasis japonicaSelenium1,2,5-oxadiazole 2-oxideAntigens, HelminthEnzyme InhibitorsMultienzyme ComplexesNADH, NADPH OxidoreductasesOxadiazolesSeleniumthioredoxin glutathione reductaseAnti-schistosomiasisFuroxanOxadiazole-2-oxidesSchistosoma japonicumSjTGR

Identifiers

PMID33902686
PMCPMC8074465
OpenAlexW3125778769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.